IIT2025-03-YANG-LIFT-HCC

Conditions

• Hepato Cellular Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA) — DRUG
  • To assess the success rate of combining ICIs and LRT (as neoadjuvant treatment) in tumor downstaging to Milan Criteria within 12 months of baseline STRIDE treatment in patients with HCC exceeding the University of California San Francisco (UCSF) criteria.

Study Details

The investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC). The goal is to try to lower the stage of the cancer so that more patients may become eligible for a liver transplant. The investigators will also closely watch for side effects from the study treatments. Section 2 has more details.

Key Dates

Start date

Apr 1, 2026

Status verified

Mar 2026

Primary completion

Apr 1, 2030

Completion

Dec 31, 2030

Study Design

Enrollment

41 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Age ≥ 18 Patients with HCC beyond UCSF criteria, ECOG performance status ≤ 2, and Child-Pugh A or B7
  STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)

Primary Outcome Measure

Proportion of participants downstaged from beyond UCSF criteria to within Milan criteria by radiographic assessment [ Time Frame: 12 month ]

Central Contacts

• Ju Dong Yang, MD
  310-423-6000
  [email protected]
• Manaf Alsudaney, MD
  3109677454
  [email protected]

Locations (1)

Find similar trials in Los Angeles, CA